PortalPublikationenKidney outcome after mild to moderate COVID-19

Kidney outcome after mild to moderate COVID-19

Standard

Kidney outcome after mild to moderate COVID-19. / Schmidt-Lauber, Christian; Hänzelmann, Sonja; Schunk, Stefan; Petersen, Elina L; Alabdo, Ammar; Lindenmeyer, Maja; Hausmann, Fabian; Kuta, Piotr; Renné, Thomas; Twerenbold, Raphael; Zeller, Tanja; Blankenberg, Stefan; Fliser, Danilo; Huber, Tobias B.

in: NEPHROL DIAL TRANSPL, Jahrgang 38, Nr. 9, 31.08.2023, S. 2031-2040.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schmidt-Lauber, C, Hänzelmann, S, Schunk, S, Petersen, EL, Alabdo, A, Lindenmeyer, M, Hausmann, F, Kuta, P, Renné, T, Twerenbold, R, Zeller, T, Blankenberg, S, Fliser, D & Huber, TB 2023, 'Kidney outcome after mild to moderate COVID-19', NEPHROL DIAL TRANSPL, Jg. 38, Nr. 9, S. 2031-2040. https://doi.org/10.1093/ndt/gfad008

APA

Schmidt-Lauber, C., Hänzelmann, S., Schunk, S., Petersen, E. L., Alabdo, A., Lindenmeyer, M., Hausmann, F., Kuta, P., Renné, T., Twerenbold, R., Zeller, T., Blankenberg, S., Fliser, D., & Huber, T. B. (2023). Kidney outcome after mild to moderate COVID-19. NEPHROL DIAL TRANSPL, 38(9), 2031-2040. https://doi.org/10.1093/ndt/gfad008

Vancouver

Schmidt-Lauber C, Hänzelmann S, Schunk S, Petersen EL, Alabdo A, Lindenmeyer M et al. Kidney outcome after mild to moderate COVID-19. NEPHROL DIAL TRANSPL. 2023 Aug 31;38(9):2031-2040. https://doi.org/10.1093/ndt/gfad008

Bibtex

@article{a0df5cf82f764f7a8c023493cf6c3563,
title = "Kidney outcome after mild to moderate COVID-19",
abstract = "BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a remarkable kidney tropism. While kidney effects are common in severe coronavirus disease 2019 (COVID-19), data on non-severe courses are limited. Here we provide a multilevel analysis of kidney outcomes after non-severe COVID-19 to test for eventual kidney sequela.METHODS: This cross-sectional study investigates individuals after COVID-19 and matched controls recruited from the Hamburg City Health Study (HCHS) and its COVID-19 program. The HCHS is a prospective population-based cohort study within the city of Hamburg, Germany. During the COVID-19 pandemic the study additionally recruited subjects after polymerase chain reaction-confirmed SARS-CoV-2 infections. Matching was performed by age, sex and education. Main outcomes were estimated glomerular filtration rate (eGFR), albuminuria, Dickkopf3, haematuria and pyuria.RESULTS: A total of 443 subjects in a median of 9 months after non-severe COVID-19 were compared with 1328 non-COVID-19 subjects. The mean eGFR was mildly lower in post-COVID-19 than non-COVID-19 subjects, even after adjusting for known risk factors {β = -1.84 [95% confidence interval (CI) -3.16 to -0.52]}. However, chronic kidney disease [odds ratio (OR) 0.90 (95% CI 0.48-1.66)] or severely increased albuminuria [OR 0.76 (95% CI 0.49-1.09)] equally occurred in post-COVID-19 and non-COVID-19 subjects. Haematuria, pyuria and proteinuria were also similar between the two cohorts, suggesting no ongoing kidney injury after non-severe COVID-19. Further, Dickkopf3 was not increased in the post-COVID-19 cohort, indicating no systematic risk for ongoing GFR decline [β = -72.19 (95% CI -130.0 to -14.4)].CONCLUSION: While mean eGFR was slightly lower in subjects after non-severe COVID-19, there was no evidence for ongoing or progressive kidney sequela.",
author = "Christian Schmidt-Lauber and Sonja H{\"a}nzelmann and Stefan Schunk and Petersen, {Elina L} and Ammar Alabdo and Maja Lindenmeyer and Fabian Hausmann and Piotr Kuta and Thomas Renn{\'e} and Raphael Twerenbold and Tanja Zeller and Stefan Blankenberg and Danilo Fliser and Huber, {Tobias B}",
note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.",
year = "2023",
month = aug,
day = "31",
doi = "10.1093/ndt/gfad008",
language = "English",
volume = "38",
pages = "2031--2040",
journal = "NEPHROL DIAL TRANSPL",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Kidney outcome after mild to moderate COVID-19

AU - Schmidt-Lauber, Christian

AU - Hänzelmann, Sonja

AU - Schunk, Stefan

AU - Petersen, Elina L

AU - Alabdo, Ammar

AU - Lindenmeyer, Maja

AU - Hausmann, Fabian

AU - Kuta, Piotr

AU - Renné, Thomas

AU - Twerenbold, Raphael

AU - Zeller, Tanja

AU - Blankenberg, Stefan

AU - Fliser, Danilo

AU - Huber, Tobias B

N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.

PY - 2023/8/31

Y1 - 2023/8/31

N2 - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a remarkable kidney tropism. While kidney effects are common in severe coronavirus disease 2019 (COVID-19), data on non-severe courses are limited. Here we provide a multilevel analysis of kidney outcomes after non-severe COVID-19 to test for eventual kidney sequela.METHODS: This cross-sectional study investigates individuals after COVID-19 and matched controls recruited from the Hamburg City Health Study (HCHS) and its COVID-19 program. The HCHS is a prospective population-based cohort study within the city of Hamburg, Germany. During the COVID-19 pandemic the study additionally recruited subjects after polymerase chain reaction-confirmed SARS-CoV-2 infections. Matching was performed by age, sex and education. Main outcomes were estimated glomerular filtration rate (eGFR), albuminuria, Dickkopf3, haematuria and pyuria.RESULTS: A total of 443 subjects in a median of 9 months after non-severe COVID-19 were compared with 1328 non-COVID-19 subjects. The mean eGFR was mildly lower in post-COVID-19 than non-COVID-19 subjects, even after adjusting for known risk factors {β = -1.84 [95% confidence interval (CI) -3.16 to -0.52]}. However, chronic kidney disease [odds ratio (OR) 0.90 (95% CI 0.48-1.66)] or severely increased albuminuria [OR 0.76 (95% CI 0.49-1.09)] equally occurred in post-COVID-19 and non-COVID-19 subjects. Haematuria, pyuria and proteinuria were also similar between the two cohorts, suggesting no ongoing kidney injury after non-severe COVID-19. Further, Dickkopf3 was not increased in the post-COVID-19 cohort, indicating no systematic risk for ongoing GFR decline [β = -72.19 (95% CI -130.0 to -14.4)].CONCLUSION: While mean eGFR was slightly lower in subjects after non-severe COVID-19, there was no evidence for ongoing or progressive kidney sequela.

AB - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a remarkable kidney tropism. While kidney effects are common in severe coronavirus disease 2019 (COVID-19), data on non-severe courses are limited. Here we provide a multilevel analysis of kidney outcomes after non-severe COVID-19 to test for eventual kidney sequela.METHODS: This cross-sectional study investigates individuals after COVID-19 and matched controls recruited from the Hamburg City Health Study (HCHS) and its COVID-19 program. The HCHS is a prospective population-based cohort study within the city of Hamburg, Germany. During the COVID-19 pandemic the study additionally recruited subjects after polymerase chain reaction-confirmed SARS-CoV-2 infections. Matching was performed by age, sex and education. Main outcomes were estimated glomerular filtration rate (eGFR), albuminuria, Dickkopf3, haematuria and pyuria.RESULTS: A total of 443 subjects in a median of 9 months after non-severe COVID-19 were compared with 1328 non-COVID-19 subjects. The mean eGFR was mildly lower in post-COVID-19 than non-COVID-19 subjects, even after adjusting for known risk factors {β = -1.84 [95% confidence interval (CI) -3.16 to -0.52]}. However, chronic kidney disease [odds ratio (OR) 0.90 (95% CI 0.48-1.66)] or severely increased albuminuria [OR 0.76 (95% CI 0.49-1.09)] equally occurred in post-COVID-19 and non-COVID-19 subjects. Haematuria, pyuria and proteinuria were also similar between the two cohorts, suggesting no ongoing kidney injury after non-severe COVID-19. Further, Dickkopf3 was not increased in the post-COVID-19 cohort, indicating no systematic risk for ongoing GFR decline [β = -72.19 (95% CI -130.0 to -14.4)].CONCLUSION: While mean eGFR was slightly lower in subjects after non-severe COVID-19, there was no evidence for ongoing or progressive kidney sequela.

U2 - 10.1093/ndt/gfad008

DO - 10.1093/ndt/gfad008

M3 - SCORING: Journal article

C2 - 36657383

VL - 38

SP - 2031

EP - 2040

JO - NEPHROL DIAL TRANSPL

JF - NEPHROL DIAL TRANSPL

SN - 0931-0509

IS - 9

ER -